Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin declines year over year
Q3 FY2026 selling, general & admin of $407.9M fell 23.1% year over year, behind the -12.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at +8.5% a year.
Context
- Selling, general & admin amounted to 42.4% of revenue in FY2025, up 8.4 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 16 analysts of $1.89B (+4.7%) for the fiscal year ending Dec 2026, a slowdown from the +30.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $407.9M+4.8% QoQ
- Last fiscal yearDec 2025
- $1.81B+30.6% YoY
- LTMSep 2026
- $1.56B-12.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.81B USD
- Year-over-year change
- +30.6%
- 4-year CAGR
- +5.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.81B | +30.6% |
| FY2024 | 2024-12-31 | 1.39B | +3.1% |
| FY2023 | 2023-12-31 | 1.34B | -5.2% |
| FY2022 | 2022-12-31 | 1.42B | -2.4% |
| FY2021 | 2021-12-31 | 1.45B | — |
Selling, General & Admin vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's LTM Sep 2026 selling, general & admin of $1.56B is the highest of the 9 companies compared; the peer median is $335.63M.
- Its year-over-year change of -12.2% is the 7th highest of 8, against a peer median of +14.2%.
- Selling, general & admin amounts to 33.0% of revenue for JAZZ, versus a peer median of 27.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.56B | -12.2% | +8.5% | 33.0% | |
| LTM Sep 2026 | $1.43B | +24.9% | +15.4% | 38.5% | |
| LTM Jun 2026 | $1.4B | +8.2% | +11.2% | 24.0% | |
| LTM Jun 2026 | $726.99M | — | -39.2% | 17.6% | |
| LTM Sep 2026 | $357.49M | +10.5% | +25.2% | 26.3% | |
| LTM Sep 2026 | $313.76M | +50.7% | +34.4% | 34.9% | |
| LTM Jun 2026 | $272.47M | +14.2% | +18.5% | 28.4% | |
| LTM Jun 2026 | $103.43M | +16.1% | +9.7% | 35.6% | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| Peer median (excluding JAZZ) | $335.63M | +14.2% | +13.3% | 27.4% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B |
| Cost of Revenue | 440.76M | 540.52M | 435.58M | 445.71M | 503.3M |
| Gross Profit | 2.65B | 3.12B | 3.4B | 3.62B | 3.76B |
| Gross Margin | 85.8% | 85.2% | 88.6% | 89.0% | 88.2% |
| Research & Development | 505.75M | 590.45M | 849.66M | 884M | 782.74M |
| Selling, General & Admin | 1.45B | 1.42B | 1.34B | 1.39B | 1.81B |
| Operating Expenses | 2.48B | 3.18B | 2.82B | 2.91B | 3.54B |
| Depreciation & Amortization | 552.48M | 629.47M | 638.7M | 660.07M | 696.3M |
| EBITDA | 1.03B | 1.47B | 1.45B | 1.52B | 262.76M |
| EBITDA Margin | 33.2% | 40.1% | 37.8% | 37.4% | 6.2% |
| Operating Income | 170.28M | (65.53M) | 578.58M | 716.63M | 224.42M |
| Operating Margin | 5.5% | -1.8% | 15.1% | 17.6% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 278.77M | 288.24M | 289.44M | 238.1M | 195.05M |
| Other Income / Expenses | (283.83M) | (317.18M) | (283.66M) | (247.94M) | (853.01M) |
| Income Before Tax | (113.55M) | (382.71M) | 294.92M | 468.69M | (628.59M) |
| Pre-Tax Margin | -3.7% | -10.5% | 7.7% | 11.5% | -14.7% |
| Income Tax Expense | 216.12M | (158.65M) | (119.91M) | (91.43M) | (272.44M) |
| Net Income | (328.95M) | (224.06M) | 414.83M | 560.12M | (356.15M) |
| Net Margin | -10.6% | -6.1% | 10.8% | 13.8% | -8.3% |
| EPS (Basic) | (5.51) | (3.58) | 6.55 | 9.06 | (5.84) |
| EPS (Diluted) | (5.51) | (3.58) | 6.10 | 8.65 | (5.84) |
| Weighted Avg Shares | 59.69M | 62.54M | 63.29M | 61.84M | 60.98M |
| Weighted Avg Shares (Diluted) | 59.69M | 62.54M | 72.07M | 66.01M | 60.98M |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.